Should Value Investors Buy Teva Pharmaceutical Industries (TEVA) Stock?Zacks Investment Research • 05/13/24
Teva Pharmaceutical Industries (TEVA) Q1 Earnings: How Key Metrics Compare to Wall Street EstimatesZacks Investment Research • 05/08/24
Teva Surges To 5-Year High On Maintained Outlook Despite Mixed First QuarterInvestors Business Daily • 05/08/24
Teva Reports First Quarter 2024 Financial Results and Reaffirms 2024 Financial OutlookBusiness Wire • 05/08/24
Teva and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable in Adults with SchizophreniaBusiness Wire • 05/08/24
Unlocking Q1 Potential of Teva Pharmaceutical Industries (TEVA): Exploring Wall Street Estimates for Key MetricsZacks Investment Research • 05/03/24
Teva's 2023 Healthy Future Report Showcases Renewed Sustainability Strategy and Ambitious TargetsBusiness Wire • 05/02/24
Teva's New Real-World Evidence Presented at the 2024 AAN Annual Meeting Confirms Effectiveness and Patient Satisfaction for HD Chorea with the 4-week Titration Kit for AUSTEDO® (deutetrabenazine) TabletsBusiness Wire • 04/16/24
Teva Confirms Efficacy and Safety of AJOVY® (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in ChinaBusiness Wire • 04/11/24
Teva to Host Conference Call to Discuss First Quarter 2024 Financial Results at 8 a.m. ET on May 8, 2024Business Wire • 04/09/24
Forget Nvidia: 3 Prominent Billionaire Investors Are Selling It and Buying These 6 Value Stocks InsteadThe Motley Fool • 04/08/24
New Pharmacokinetic Modeling Data Presented by Teva Simulates Clinical Profiles of Schizophrenia Patients Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension at SIRS 2024Business Wire • 04/06/24
Teva and mAbxience Announce Strategic Global Licensing Agreement for Oncology Biosimilar CandidateBusiness Wire • 04/04/24